KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Intangibles (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 9 years of Intangibles data on record, last reported at $108.9 million in Q4 2025.

  • For Q4 2025, Intangibles fell 9.09% year-over-year to $108.9 million; the TTM value through Dec 2025 reached $108.9 million, down 9.09%, while the annual FY2025 figure was $108.9 million, 9.09% down from the prior year.
  • Intangibles reached $108.9 million in Q4 2025 per ACAD's latest filing, down from $111.6 million in the prior quarter.
  • Across five years, Intangibles topped out at $119.8 million in Q4 2024 and bottomed at $369000.0 in Q2 2021.
  • Average Intangibles over 4 years is $84.0 million, with a median of $106.7 million recorded in 2024.
  • Peak YoY movement for Intangibles: plummeted 80.01% in 2021, then surged 82.9% in 2024.
  • A 4-year view of Intangibles shows it stood at $369000.0 in 2021, then skyrocketed by 17647.97% to $65.5 million in 2023, then skyrocketed by 82.9% to $119.8 million in 2024, then fell by 9.09% to $108.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Intangibles were $108.9 million in Q4 2025, $111.6 million in Q3 2025, and $114.3 million in Q2 2025.